Roquefort Therapeutics (LON:ROQ) Shares Down 1% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s stock price fell 1% during mid-day trading on Friday . The stock traded as low as GBX 2.08 ($0.03) and last traded at GBX 2.08 ($0.03). 1,005,907 shares traded hands during trading, a decline of 53% from the average session volume of 2,129,146 shares. The stock had previously closed at GBX 2.10 ($0.03).

Roquefort Therapeutics Stock Down 15.2%

The firm’s fifty day moving average price is GBX 1.81 and its 200-day moving average price is GBX 1.68. The company has a market capitalization of £2.80 million, a price-to-earnings ratio of -282.54 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07.

Roquefort Therapeutics (LON:ROQ) last issued its quarterly earnings data on Tuesday, September 30th. The company reported GBX (0.33) earnings per share for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.